DR. JOHANNA MARGARET SEDDON, MD
Medical Practice in Boston, MA

2011017, Jul 21, 2011

Apr 17, 2009

12/988340

Johanna M. Seddon - Boston MA, US
Mark Daly - Arlington MA, US

Tufts Medical Center, Inc., (f/k/a/ New England Medical Center Hospitals, Inc.) - Boston MA

C12Q 1/68, C40B 30/00, C07H 21/00, C40B 40/06, C40B 60/12

506 7, 435 61, 435 611, 435 619, 536 231, 506 16, 506 39

The present invention provides for certain polynucleotide sequences that have been correlated to AMD. These polynucleotides are useful as diagnostics, and are preferably used to fabricate an array, useful for screening patient samples. The array is used as part of a laboratory information management system, to store and process additional patient information in addition to the patient's genomic profile. As described herein, the system provides an assessment of the patient's risk for developing AMD, risk for disease progression, and the likelihood of disease prevention based on patient controllable factors.

2009011, Apr 30, 2009

May 12, 2008

12/119108

Johanna M. Seddon - Boston MA, US
Mark J. Daly - Arlington MA, US

C40B 30/04, C12Q 1/68, C07H 21/04, C40B 40/08, C40B 60/12, C40B 50/14

506 9, 435 6, 536 2431, 506 17, 506 39, 506 30

The present invention provides for certain polynucleotide sequences that have been correlated to AMD. These polynucleotides are useful as diagnostics, and are preferably used to fabricate an array, useful for screening patient samples. The array is used as part of a laboratory information management system, to store and process additional patient information in addition to the patient's genomic profile. As described herein, the system provides an assessment of the patient's risk for developing AMD, risk for disease progression, and the likelihood of disease prevention based on patient controllable factors.

2013002, Jan 24, 2013

Aug 24, 2012

13/594304

Johanna M. Seddon - Boston MA, US
Mark J. Daly - Arlington MA, US

THE GENERAL HOSPITAL CORPORATION - Boston MA
TUFTS MEDICAL CENTER, INC. - Boston MA

C12Q 1/28, C40B 30/04

506 9, 435 611

The present invention provides for certain polynucleotide sequences that have been correlated to AMD. These polynucleotides are useful as diagnostics, and are preferably used to fabricate an array, useful for screening patient samples. The array is used as part of a laboratory information management system, to store and process additional patient information in addition to the patient's genomic profile. As described herein, the system provides an assessment of the patient's risk for developing AMD, risk for disease progression, and the likelihood of disease prevention based on patient controllable factors.

2011029, Dec 1, 2011

Apr 27, 2009

12/989771

Johanna M. Seddon - Boston MA, US
Mark J. Daly - Arlington MA, US

THE GENERAL HOSPITAL CORPORATION - Boston MA
TUFTS MEDICAL CENTER, INC. - Boston MA

C40B 30/04, C12Q 1/68

506 9, 435 611

Disclosed are methods for diagnosing AMD or a susceptibility for AMD by identifying one or more markers associated with peripheral retinal phenotypes.

2010033, Dec 30, 2010

Jan 21, 2010

12/691034

Jeffrey P. Gilbard - Weston MA, US
Johanna M. Seddon - Boston MA, US

A61K 9/64, A61K 36/82, A61K 31/59, A61K 31/355, A61K 31/34, A61K 33/30, A61K 33/34, A61P 27/02

424456, 424729, 514167, 514458, 514474, 424641, 424638

Nutritional supplements for eye health comprising: an anti-oxidant component; an anti-inflammatory component; and an anti-angiogenic component. The supplements inhibit development and progression of a range of retinal diseases and degenerations, particularly AMD and diabetic eye disease, diabetic retinopathy and diabetic macular edema. The supplements include tocotrienol and green tea extract.

2009022, Sep 10, 2009

Mar 5, 2008

12/042854

Jeffrey P. Gilbard - Weston MA, US
Johanna M. Seddon - Boston MA, US

A61K 36/82, A61K 31/355, A61K 31/353, A61P 27/02, A61P 29/00

424729, 514458, 514456

Nutritional supplements for eye health comprising: an anti-oxidant component; an anti-inflammatory component; and an anti-angiogenic component. The supplements inhibit development and progression of a range of retinal diseases and degenerations, particularly AMD and diabetic eye disease, diabetic retinopathy and diabetic macular edema. The supplements include tocotrienol and green tea extract.

2005025, Nov 10, 2005

Feb 25, 2005

11/066641

Johanna Seddon - Boston MA, US

A61K031/555, A61K031/60, G01N033/92, G01N033/00

514165000, 436071000, 436086000

Provided are methods of using levels of markers of systemic inflammation, e.g., CRP, to predict a subject's risk of development or progression of Age-Related Macular Degeneration (AMD), and methods of treating, delaying or preventing the development or progression of AMD.

2012019, Jul 26, 2012

Jul 30, 2010

13/388215

Johanna M. Seddon - Boston MA, US
John Patterson Atkinson - St. Louis MO, US

WASHINGTON UNIVERSITY - St. Louis MO
TUFTS MEDICAL CENTER, INC. - Boston MA

C40B 30/04, C12Q 1/68, C40B 60/12, C40B 50/14, G01N 33/566, G01N 33/577

506 9, 436501, 435 792, 506 39, 506 30, 435 611

The present invention is directed to systems and method for predicting risk of AMD or a susceptibility to AMD in a patient by detecting elevated serum or plasma levels of C3, CFB or CFH and other complement factor polypeptides, wherein devated levels certain complement factors, genetic risk factors, medical risk factors, behavioral and environmental risk factors are associated with are indicative of susceptibility for or an increased risk of developing AMD, or an increased risk of progression of AMD in the patient.